Improved chemotherapy in disseminated testicular cancer

Lawrence Einhorn, B. Furnas

Research output: Chapter in Book/Report/Conference proceedingChapter

9 Citations (Scopus)

Abstract

Combination chemotherapy with platinum + vinblastine + bleomycin in disseminated testicular cancer has been highly successful, producing 28 complete (72%) and 11 partial (28%) remissions in 39 evaluable patients. Furthermore, an additional 5 patients have been rendered disease-free by surgical removal of residual disease, making the effective disease-free status 85%. 32 of these patients remain alive, and 25 remain alive and disease-free from 3+ to 24+ mths. Despite the significant toxicity during the first 12 wks of this therapeutic regimen, it was usually manageable and maintainance therapy produced minimal toxicity. This regimen is considered to be a major advance in the management of patients with disseminated testicular cancer.

Original languageEnglish
Title of host publicationJ.CLIN.HEMATOL.ONCOL.
Pages662-671
Number of pages10
Volume7
Edition2
StatePublished - 1977

Fingerprint

Testicular Neoplasms
Drug Therapy
Vinblastine
Combination Drug Therapy
Platinum
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Einhorn, L., & Furnas, B. (1977). Improved chemotherapy in disseminated testicular cancer. In J.CLIN.HEMATOL.ONCOL. (2 ed., Vol. 7, pp. 662-671)

Improved chemotherapy in disseminated testicular cancer. / Einhorn, Lawrence; Furnas, B.

J.CLIN.HEMATOL.ONCOL.. Vol. 7 2. ed. 1977. p. 662-671.

Research output: Chapter in Book/Report/Conference proceedingChapter

Einhorn, L & Furnas, B 1977, Improved chemotherapy in disseminated testicular cancer. in J.CLIN.HEMATOL.ONCOL.. 2 edn, vol. 7, pp. 662-671.
Einhorn L, Furnas B. Improved chemotherapy in disseminated testicular cancer. In J.CLIN.HEMATOL.ONCOL.. 2 ed. Vol. 7. 1977. p. 662-671
Einhorn, Lawrence ; Furnas, B. / Improved chemotherapy in disseminated testicular cancer. J.CLIN.HEMATOL.ONCOL.. Vol. 7 2. ed. 1977. pp. 662-671
@inbook{456c5d655dd3493f9f53224edc7242c5,
title = "Improved chemotherapy in disseminated testicular cancer",
abstract = "Combination chemotherapy with platinum + vinblastine + bleomycin in disseminated testicular cancer has been highly successful, producing 28 complete (72{\%}) and 11 partial (28{\%}) remissions in 39 evaluable patients. Furthermore, an additional 5 patients have been rendered disease-free by surgical removal of residual disease, making the effective disease-free status 85{\%}. 32 of these patients remain alive, and 25 remain alive and disease-free from 3+ to 24+ mths. Despite the significant toxicity during the first 12 wks of this therapeutic regimen, it was usually manageable and maintainance therapy produced minimal toxicity. This regimen is considered to be a major advance in the management of patients with disseminated testicular cancer.",
author = "Lawrence Einhorn and B. Furnas",
year = "1977",
language = "English",
volume = "7",
pages = "662--671",
booktitle = "J.CLIN.HEMATOL.ONCOL.",
edition = "2",

}

TY - CHAP

T1 - Improved chemotherapy in disseminated testicular cancer

AU - Einhorn, Lawrence

AU - Furnas, B.

PY - 1977

Y1 - 1977

N2 - Combination chemotherapy with platinum + vinblastine + bleomycin in disseminated testicular cancer has been highly successful, producing 28 complete (72%) and 11 partial (28%) remissions in 39 evaluable patients. Furthermore, an additional 5 patients have been rendered disease-free by surgical removal of residual disease, making the effective disease-free status 85%. 32 of these patients remain alive, and 25 remain alive and disease-free from 3+ to 24+ mths. Despite the significant toxicity during the first 12 wks of this therapeutic regimen, it was usually manageable and maintainance therapy produced minimal toxicity. This regimen is considered to be a major advance in the management of patients with disseminated testicular cancer.

AB - Combination chemotherapy with platinum + vinblastine + bleomycin in disseminated testicular cancer has been highly successful, producing 28 complete (72%) and 11 partial (28%) remissions in 39 evaluable patients. Furthermore, an additional 5 patients have been rendered disease-free by surgical removal of residual disease, making the effective disease-free status 85%. 32 of these patients remain alive, and 25 remain alive and disease-free from 3+ to 24+ mths. Despite the significant toxicity during the first 12 wks of this therapeutic regimen, it was usually manageable and maintainance therapy produced minimal toxicity. This regimen is considered to be a major advance in the management of patients with disseminated testicular cancer.

UR - http://www.scopus.com/inward/record.url?scp=0017736588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017736588&partnerID=8YFLogxK

M3 - Chapter

VL - 7

SP - 662

EP - 671

BT - J.CLIN.HEMATOL.ONCOL.

ER -